A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Study sponsor: Q32 Bio Inc. · QTTB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-06Estimated
Enrollment · participants75Estimated
Source updated2026-05-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.